1	
2	
3	Genomic reconstruction of an azole-resistant Candida parapsilosis
4	outbreak and the creation of a multilocus sequence typing scheme: a
5	retrospective observational and genomic epidemiology study
6	
7	
8	Running title: Genomic epidemiology and sequence typing of Candida parapsilosis
9	
10	
11	
12	
13	
14	Phillip Brassington, MSc ^{1,6} ; Frank-Rainer Klefisch, Dr. med ² ; Barbara Graf, Dr. med ³ ; Roland Pfüller,
15	Dr. rer. nat. ⁴ ; Oliver Kurzai, Univ. Prof. ^{5,6} ; Grit Walther, Dr. rer. nat. ^{5,8} ; Amelia E. Barber, PhD ^{1,7,8}
16	
17	
18	Address correspondence to:
19	Amelia E. Barber (<u>amelia.barber@uni-jena.de;</u> Rosalind-Franklin-Str. 1, 07745 Jena, Germany)
20	
21	
22 23 24 25 26 27 28 29 30 31	 ¹ Institute for Microbiology. Friedrich Schiller University Jena. Jena, Germany. ² Paulinen Hospital. Berlin, Germany. ³ Labor Berlin. Berlin, Germany. ⁴ MVZ Hauptstadtlabor, Labservice GmbH. Berlin, Germany. ⁵ National Reference Center for Invasive Fungal Infections (NRZMyk). Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute. Jena, Germany. ⁶ Institute for Hygiene and Microbiology. University of Würzburg. Würzburg, Germany. ⁷ Cluster of Excellence Balance of the Microverse, Friedrich Schiller University Jena, Jena, Germany. ⁸ Equal contribution

32

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 33 Summary
- 34 Background

35 Fluconazole-resistant *Candida parapsilosis* has emerged as a significant healthcare-associated

36 pathogen with a propensity to spread patient-to-patient and cause nosocomial outbreaks, similar to

37 Candida auris. This study investigates a prolonged outbreak of fluconazole-resistant C. parapsilosis

- 38 across multiple years and healthcare centers in Berlin, Germany.
- 39
- 40 <u>Methods</u>

In this retrospective observational study, we used whole-genome sequencing of isolates from the outbreak in Berlin and other regions within Germany and compared them with isolates from a global distribution to understand the molecular epidemiology of this outbreak. Additionally, we used the genomic dataset of global samples to identify loci with high discriminatory power to establish a multilocus sequence typing (MLST) strategy for *C. parapsilosis*.

- 46
- 47 Findings

48 A clonal, azole-resistant strain of C. parapsilosis was observed causing 33 cases of invasive 49 infection from 2018-2022 in multiple hospitals within the outbreak city. Whole genome sequencing revealed that outbreak strains were separated by an average of 36 single nucleotide variants, while 50 outbreak strains differed from outgroup samples from Berlin and other regions of Germany by an 51 average of 2,112 variants. Temporal and genomic reconstruction of the outbreak cases indicated 52 that transfer of patients between healthcare facilities was likely responsible for the persistent 53 reimportation of the drug-resistant clone and subsequent person-to-person transmission. German 54 outbreak strains were closely related to strains responsible for an outbreak in Canada and to others 55 56 isolated in the Middle East and East Asia. Including the outbreak clone, we identified three distinct ERG11 Y132F azole-resistant lineages in Germany, marking the first description of this azole-57 resistance in the country and its endemic status. Using the novel MLST strategy, a global collection 58 of 386 isolates was categorized into 62 sequence types, with the outbreak strains all belonging to 59 60 the same sequence type.

61

62 Interpretation

This study underscores the emergence of drug resistant fungal pathogens that can spread patient-63 to-patient within a healthcare system, but also around the globe. This highlights the importance of 64 monitoring C. parapsilosis epidemiology globally and of continuous surveillance and rigorous 65 infection control measures at the local scale. Through large-scale genomic epidemiology, our study 66 offers a high-resolution view of how a drug-resistant clone behaved in a local healthcare system and 67 how this clone fits into the global epidemiology of this pathogen. We also demonstrate the utility of 68 the novel typing scheme for genetic epidemiology and outbreak investigations as a faster and less 69 70 expensive alternative to whole genome sequencing.

71

- 72 <u>Funding</u>
- 73 German Federal Ministry for Education and Research, German Research Foundation, German
- 74 Ministry of Health

75 Research in context

76 Evidence before this study

We searched PubMed and Google Scholar from database inception to Apr 25, 2024, using the 77 search terms "Candida parapsilosis", "outbreak", "azole resistance", and/or "fluconazole" in PubMed 78 79 and Google Scholar. We applied no language or study type restrictions. The epidemiology of candidemia has undergone dramatic changes in recent years. New pathogenic species, such as 80 Candida auris, have emerged, and existing species like Candida parapsilosis have increased in 81 prominence. There has also been a worrving increase in drug resistance among *Candida* species. 82 Moreover, numerous drug-resistant outbreaks of C. parapsilosis have been reported worldwide and 83 are challenging to control due to their prolonged and intermittent nature. The overwhelming majority 84 of previous work has used microsatellite markers to infer genetic relationships among outbreaks 85 strains, obscuring whether they are really clonal in nature, our understanding of the temporal and 86 87 transmission dynamics of these outbreaks, and the genetic relationship between outbreak clones. 88

89 Added value of this study

90 This study adds to the existing evidence by utilizing whole genome sequencing in conjunction with hospital records to analyze a prolonged outbreak of clonal, azole-resistant C. parapsilosis that 91 92 occurred across multiple years and medical centers. This study demonstrates that patient transfers can result in the reimportation of outbreak clones, posting a significant challenge for infection 93 control. We also reveal that the outbreak clone is closely related to drug-resistant isolates from other 94 continents, highlighting the global spread of drug-resistant C. parapsilosis. Furthermore, the study 95 addresses the need for rapid strain differentiation in outbreak settings by establishing and validating 96 a set of four loci for Sanger sequence-based typing, which provide a highly discriminatory tool for 97 98 epidemiologic investigations.

99

100 Implications of all the available evidence

101 This study underscores the global challenge of azole-resistant C. parapsilosis and its importance as 102 the causative agent of nosocomial outbreaks. Clinicians should be aware of the evolving 103 epidemiology of C. parapsilosis and the prevalence of drug-resistant strains, emphasizing the 104 importance of appropriate antifungal stewardship and infection control measures. The study emphasizes the challenges caused by inter-hospital transmission and their role in persistent 105 106 outbreaks, highlighting the need for robust surveillance and coordination among healthcare 107 facilities. While whole genome sequencing (WGS) is becoming more widely available, it is still not 108 available in many settings due to cost, limitations in bioinformatic expertise, and the absence of 109 standardized methodology and data interpretation. The establishment of a sequence-based typing 110 scheme is a valuable tool for rapid assessment of samples, which can aid in outbreak tracking and containment efforts, and provide results more rapidly even in settings where WGS is available. 111

112 Introduction

During the last decade, the epidemiology of candidemia has seen dramatic changes due to the 113 emergence of new pathogenic species like Candida auris, and dramatic increases in the prominence 114 of existing species such as Candida parapsilosis ¹⁻³. C. parapsilosis is now the second to fourth 115 116 leading cause of systemic Candida infections and has gone from being historically associated with pediatric infection to a frequent cause of catheter-associated bloodstream infections in adults ¹. A 117 118 worrying accompaniment to the changing species epidemiology is a corresponding increase in drug resistance in Candida spp. including C. parapsilosis, Previously, isolates of C. parapsilosis were 119 overwhelmingly azole susceptible. Now, there are more than 36 studies from 15 countries 120 documenting local fluconazole resistance rates of >10% in C. parapsilosis and an exponential 121 increase in reports of fluconazole-resistant C. parapsilosis since 2019³. Fluconazole-resistant 122 invasive disease results in a three-fold increase in mortality compared to infection with a susceptible 123 strain (16% for susceptible to 50% resistant infections)⁴. The most dominant fluconazole resistance 124 mechanism seen clinically is the Y132F amino acid substitution in the azole target gene, lanosterol 125 126 14-alpha-demethylase (ERG11).

127

Alongside the rapid increase in fluconazole resistance, there has been an alarming number of drug-128 resistant outbreaks of *C. parapsilosis* reported since 2018 ^{5–13}. This organism is commonly found on 129 the skin, and, as a result, it can spread within healthcare facilities in a patient-to-patient manner 130 through contaminated medical devices, environmental surfaces, or the hands of healthcare workers 131 ^{5,9}. Outbreaks of *C. parapsilosis* can also persist despite strict infection control strategies and may 132 show gaps in the occurrence of outbreak strains ^{3,14}. Recognition of nosocomial outbreaks and 133 implementation of successful infection control measures requires a rapid and reproducible method for 134 135 discriminating closely related isolates. However, there is currently no gold standard for strain typing in C. parapsilosis. Currently, the most widely used method is a species-specific set of microsatellite 136 markers ¹⁵. However, microsatellite typing requires specialized equipment, is prone to PCR artifacts, 137 and requires specialized knowledge for interpretation ¹⁶. Moreover, microsatellite-based typing results 138 are not as easily shared and compared across centers. Whole genome sequencing (WGS) has 139 140 exceptional resolution for discriminating between closely related isolates and is incredibly valuable for outbreak investigation, as has been demonstrated for *C. auris*^{17,18}. However, WGS is not feasible for 141 many settings due to its cost, time to result, and limitations in trained personnel to analyze the data. 142 143 The aim of this study was to investigate a prolonged outbreak of azole-resistant C. parapsilosis using 144 WGS to understand its epidemiology and to introduce a sequence typing strategy for rapid and inexpensive outbreak investigations. 145

146

147 Methods

148 Study design, outbreak description, and isolate collection

In this retrospective, national study, the genomes of *C. parapsilosis* isolates sent to the NRZMyk were
 sequenced. Samples were submitted by German healthcare facilities and laboratories for

susceptibility testing between 2016 and 2022. All potential outbreak samples were included in the study based on the following criteria: samples originated from Berlin, samples were resistant to fluconazole (FLC^R) and voriconazole (VOR^R), and were susceptible to posaconazole. Non-outbreak isolates were selected for inclusion in the study from the NRZMyk strain collection as follows: all strains that originated from outside Berlin and displayed resistance to one or more azole were included. For the azole resistant samples from outside Berlin, a matched number of azole susceptible strains from the city were randomly selected for inclusion from the NRZMyk collection.

158

Outbreak cases were initially detected in December 2018 and January 2019 by physicians at Hospital 159 #1 (name anonymized for privacy) (Figure 1a), who noticed an increase in isolates with a distinct 160 antifungal susceptibility profile. The isolates were resistant to fluconazole (FLC^R) and voriconazole 161 (VOR^R), but susceptible to other triazoles. After a period of approximately five months, during which 162 no FLC^R and VOR^R infections were reported at Hospital #1, infection isolates with this susceptibility 163 profile were once again observed (Figure 1a). The outbreak was officially declared at that time 164 (October 2019) and was formally investigated including environmental surveillance. As 165 166 C. parapsilosis is known to colonize the ear, 21 ICU patients at Hospital #1 were screened with swabs of both ears, but none were positive for C. parapsilosis. To investigate possible transfer by staff, 167 168 sixteen bedside stethoscopes were screened. Only one sample was positive, but the resulting C. parapsilosis isolate was azole susceptible. To prevent further cases, emphasis was placed on 169 hygiene measures and hand disinfection. Following implementation of the infection control measures 170 there was a nine-month period without FLC^R and VOR^R isolates reported. However, additional cases 171 172 were detected in September 2021 and the start-stop pattern continued through 2022 (Figure 1a). 173 Consultations with other hospitals and clinical laboratories in Berlin identified C. parapsilosis 174 infections with the same antifungal susceptibility profile at five other institutions (H0, H8, H9, H10, 175 H14). As outbreaks of *C. parapsilosis* are being increasingly reported, there is an urgent need for a rapid and reproducible tool capable of differentiating isolates. Motivated by this, we also set out to 176 identify a minimal set of loci that could be used for Sanger sequence-based typing for both outbreak 177 178 detection and epidemiology in our study. The Ethics Committee of the University Hospital Jena 179 approved this study under registration number 2024-3255-Daten.

180

181 <u>Procedures</u>

182 Antifungal susceptibility testing was performed by the NRZMyk using the methodology described in appendix 1 p 2. For tracking outbreak dynamics, admission and discharge records were obtained for 183 184 all outbreak patients beginning January 2018, corresponding to one year before the first detected outbreak case, and extending to December 2022 and the network of patient transfer manually 185 186 assembled. These dates correspond to roughly 12 months prior to the first case and extending until there had been several months without new cases in 2022. Patient information, including date of birth, 187 sex, underlying disease, and antifungal treatment history, was obtained from the intake form of the 188 189 NRZMyk.The NRZMyk does not collect information on patient ethnicity or race.

190

191 <u>Whole genome sequencing and computational analysis.</u>

192 DNA extraction was performed as described in the appendix 1 p 2. Library preparation and paired end sequencing was performed by GeneWiz (Leipzig, Germany) or Novogene (Cambridge, UK) using 193 194 the Illumina MiSeq platform and NovaSeq platforms, respectively (Illumina, San Diego, CA, USA). 195 One outbreak sample was sequenced a second time using new outgrowth and DNA extraction from 196 the freezer stock to assess the degree of technical variation between sequencing runs. Illumina data 197 of global samples was obtained from the NCBI Sequence Read Archive and was included in all 198 analyses except for those exclusively examining outbreak samples or comparisons between outbreak 199 and other German samples. Sequence data quality control, processing, and identification of variants 200 are described in appendix 1 p 2. The SNV-based phylogeny and all SNV distance-based analyses only considered variant positions with non-zero coverage in all 386 samples. Additional information 201 202 about phylogeny construction, how genetic distances were calculated, and root-to-tip regression for 203 assessing clock-like evolution are detailed in appendix 1 pp 2-3.

204

205 <u>Sequence typing</u>

The process by which loci were screened and identified for sequence typing and how the number of 206 207 loci was selected is described in appendix 1 p 3. PCR amplification of typing loci was performed using the primers and cycling parameters described in Table 2. Our Sanger sequence provider did not report 208 heterozygous sites with IUPAC codes and performed background subtraction, which in rare cases 209 210 erroneously removed a heterozygous peak. These were resolved by requesting the unprocessed 211 chromatograms and manually reviewing them to ensure that IUPAC bases were reported correctly. 212 The samples used for validation were collected from three hospitals in Berlin and were suspected to be additional outbreak cases based on their antifungal susceptibility profile (FLC^R, VOR^R, POS^S) and 213 214 their isolation from hospitals with previous outbreak cases.

215

Hunter's discriminatory power was calculated as follows, where N represents the number of strains
tested and x_j the number of strains belonging to the jth type:

218

$$D = 1 - \frac{1}{N(N-1)} \sum_{j=1}^{S} x_j (x_j - 1)$$

219

220 <u>Statistical analysis</u>

Statistical analyses were performed using R version 4.3.1 and significance was defined as p < 0.05. Mann-Whitney U test was used to determine the pairwise genetic difference between outbreak and outgroup strains. Spearman correlation was used to assess the relationship between isolate date and root-to-tip distance. ANOVA followed by Tukey's HDS test was used to test for pairwise SNV differences between the outbreak strains and the closely related strains from other countries.

226

227 Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation,or writing of the report.

230

231 Results

In this study, we included 38 outbreak isolates from 33 cases identified through epidemiological and 232 genomic investigations. All isolates were fluconazole resistant with a median MIC of 64 mg/L (IQR 16 233 to >64) and voriconazole (median MIC 1 mg/l; IQR 1.25), but susceptible to posaconazole (Table 1). 234 235 We also included 38 non-outbreak isolates from the NRZMyk, originating from unlinked hospitals in 236 Berlin and outside Berlin displaying resistance to one or more azole (Table 1). Most outbreak cases 237 were first reported as wound infections (39%; 12/33), followed by infections associated with central venous catheters (29%; 9/33) (Table 1). Antifungal treatment histories were available for 30 cases 238 239 (appendix 1 p 5). 33% (10/30) of patients were treated with an azole within 60 days of C. parapsilosis 240 isolation, while a larger proportion (53%; 16/30) were treated with an echinocandin within the previous 241 60 days (Table 1). The defined daily dose per 100 bed days of azole antifungals at Hospital #1 was 242 similar to that of other care level three hospitals in the region and remained largely stable over the 243 five-year study period (appendix 1 p 5).

244

Reconstructing the outbreak transmission dynamics revealed that even though the largest fraction of 245 cases (n = 20) were diagnosed at Hospital #1, most of these patients had been directly transferred to 246 this facility from a major surgical facility (Hospital #0 in Figure 1b). Supporting nosocomial 247 248 transmission, 94% of outbreak cases (31/33) had verified temporal overlap with other cases. Ward information was available for 28 cases at hospitals H1 and H14, revealing five patient clusters of 21 249 250 patients with spatial and temporal overlap on the same ward at the same time as other outbreak cases, strongly supporting patient-to-patient spread (Figure 1c). Altogether, we report a multiyear, 251 sporadic outbreak of azole-resistant C. parapsilosis in Germany that was not limited to any single 252 hospital but involved a network of hospitals in Berlin. 253

254

To examine the genomic relationship between the included isolates, we performed whole genome sequencing (WGS). 68% (51/75) of the sequenced samples originated from Berlin, including 38 isolates from the 33 cases identified to be part of the outbreak and 13 non-linked isolates from different medical centers in Berlin. Publicly available data for an additional 311 samples was included to facilitate comparison with the global *C. parapsilosis* population, bringing the total number to 386 genomes. WGS samples analyzed had a mean depth of coverage of 123x±80 (SD) (appendix 2).

261

When built into a phylogeny, we did not observe a strong population structure among the 386 samples and no lineage was unique to a particular country or continent (Figure 2). The close genetic relationship between the outbreak isolates was evident by their tight grouping and short branch lengths, supporting the nosocomial transmission that was inferred from the outbreak reconstruction.

266 The guasi-clonal relationship between outbreak isolates was further confirmed by pairwise single nucleotide variant (SNV) analysis, where isolates in the outbreak clade differed by an average of 267 268 36±20 SNVs (SD) (Figure 3). In contrast, the mean number of SNVs between outbreak samples and 269 non-outbreak isolates from other locations in Germany was significantly higher at 2,112± 828 SNVs SD (p < 0.0001, Mann-Whitney U test). Further, the number of SNVs observed between duplicate 270 sequencing of the same freezer stock of an isolate was 15, indicating that the number of SNV 271 272 differences between repeat sequencing of the same sample was similar to the genetic differentiation between outbreak isolates. We did not detect an obvious spatial-genetic relationship among outbreak 273 isolates but did observe some evidence of clock-like evolution (appendix 1 p 7, Spearman R = 0.36, 274 275 p = 0.063).

276

Strikingly, samples from Turkey¹⁹, Canada¹³, South Korea²⁰, and Kuwait²¹ were closely related to the 277 Berlin outbreak strains (Figure 2). The Canadian isolates were reported as part of a drug resistant 278 279 outbreak, revealing that this lineage has caused outbreaks on multiple continents. Although closely 280 related, the strains from each geographic region could still be distinguished by pairwise SNV 281 differences and were more similar to each other than to the other regions (appendix 1 p 8). Interestingly, despite their close genetic relationship and all strains being fluconazole resistant, 282 283 multiple resistance mechanisms were present. The strains from Berlin and Turkey carried an ERG11 Y132F mutation, while strains from Canada were ERG11 K143R (another mutation associated with 284 fluconazole resistance) and those from South Korea were ERG11 wild-type. Altogether, whole 285 genome sequencing confirmed the close genetic relationship of the outbreak strains and the presence 286 287 of this lineage in multiple other countries.

288

289 ERG11 Y132F was the dominant azole resistant mechanism across all German isolates, with 82% of resistant isolates possessing this mutation (n = 38/38 outbreak; n = 5/13 non-outbreak). Interestingly, 290 the non-outbreak Y132F strains were in two distantly related groups of samples based on the 291 phylogeny (Figure 2; appendix 1 p 9). Each of these Y132F phylogroups contained isolates from 292 293 geographically distant regions, suggesting that there are at least 3 distinct lineages of Y132F C. 294 parapsilosis circulating widely in Germany. We also observed three closely related but unlinked 295 samples from different cities in Germany that were pan-azole resistant and carried a G458S substitution in ERG11 (Figure 2; appendix 1 p 9) that has been linked to pan-azole resistance 296 297 previously ^{7,22,23}. Also included in our dataset were six newly-sequenced isolates that were resistant 298 to one or more azoles, but did not contain any resistance-associated polymorphisms in ERG11. These 299 isolates contained sequence polymorphisms in several genes that have been linked to drug 300 resistance, including the efflux pumps MDR1 and CDR1B, the multidrug resistance gene regulator 301 MRR1, and the transcriptional activator TAC1 (appendix 1 pp 12-13). While a causal role for most of these polymorphisms in drug resistance have not been experimentally established, one resistant 302 303 isolate harbored a L518F substitution in TAC1 experimentally proven to confer azole resistance in 304 vitro²⁴.

305

306 Our analysis to select loci suitable for Sanger sequence-based typing identified four 750 bp loci in 307 CPAR2 101400, CPAR2 101470, CPAR2 108720, and CPAR2 808110 (Table 2). These loci the 386 308 isolates into 62 unique sequence types (appendix 3) with a Hunter's Discriminatory Power of 0.93. 309 Discriminatory power assumes unrelated strains, while our dataset contains multiple outbreaks and 310 sets of serial isolates. When the global dataset was pruned as described in appendix 1 p3, the 311 discriminatory power rose to 0.98. Conversely, C. parapsilosis is a diploid organism and an 312 appreciable fraction of the discriminatory power comes from whether sequence polymorphisms were 313 heterozygous or homozygous. When site zygosity was not considered, we were only able to identify 314 43 sequence types across the 386 samples and the discriminatory power was dropped to 0.90. The 315 four selected loci showed a high degree of agreement with the whole genome phylogeny and were 316 able to correctly identify samples to their whole genome-defined genetic cluster with 97.1% sensitivity 317 (0.951-0.982 95% CI) and 99.8% specificity (0.997-0.99 95% CI) (appendix 1 p 6). To confirm that 318 the selected loci were present as a single copy and the discriminatory power was not being inflated 319 by the presence of multiple copies in the genome, we assessed them for genome-wide copy number 320 changes. We did not detect any CNV changes at these loci, either additional copies or loss of the 321 region (appendix 1 p 10).

322

We validated our *in silico* typing using the primers in Table 2 and a representative 13 samples from our dataset, including four outbreak strains expected to have identical sequence type profiles. In each sample, we detected all anticipated variants by Sanger sequencing and did not discover any variants that were not in the whole genome data (appendix 1 p 14). As expected, the four outbreak samples had identical sequences at the four loci and were assigned to the same sequence type. To facilitate the typing of novel isolates by researchers and clinical labs, FASTA alignments containing representative allelic sequences of the four markers are provided as appendices 4-7.

330

Finally, we demonstrated the utility of the MLST scheme on seven isolates that were not part of the dataset used to create the typing scheme, but were suspected to be additional outbreak cases based on submitting hospital and antifungal susceptibility profiles (appendix 1 p 4). Their sequence type was identical to the outbreak isolates (appendix 1 p 14), suggesting that they were outbreak cases 26-32 (Figure 1a), which was confirmed by WGS. Taken together, we identified and validated four loci that can be used for sequence-based typing of *C. parapsilosis* and demonstrated their value in rapidly identifying closely related samples.

338

339 Discussion

In this work, we use genomic epidemiology coupled with patient tracking to investigate an outbreak

of *ERG11* Y132F azole-resistant *C. parapsilosis* that occurred over several years and medical

342 centers in Berlin, Germany. We use a large-scale genomic dataset composed of 386 *C. parapsilosis*

isolates to investigate outbreak dynamics, confirm the high degree of relatedness among outbreak

isolates, and compare them to isolates from around the world—revealing that the outbreak clone is
closely related to samples from several other continents. Based on the increasing number of
outbreaks for *C. parapsilosis* and the need to rapidly discriminate between isolates, we also
establish and validate a set of four loci for Sanger sequence-based strain typing.

348

349 Due to slow outbreak kinetics and the low case density, the outbreak might have gone unnoticed if not for the atypical susceptibility pattern that was detected by clinicians and clinical microbiologists. 350 351 The reconstructed transmission dynamics suggest that outbreaks of C. parapsilosis may result from 352 the reintroduction of outbreak strains from other hospitals, underlining the challenges of outbreak 353 control and the need for heightened infection control measures. In our case, patient transfers were a 354 common occurrence among cases and facilitated inter-hospital transmission and subsequent intrahospital transmission. Unfortunately, high-resolution temporal and spatial monitoring of patients is 355 356 lacking for other outbreaks, so it is unclear the degree to which this has driven other reported 357 C. parapsilosis outbreaks. However, the pattern of prolonged but tightly related isolates causing disease across several years and multiple medical centers matches other outbreak reports ^{10,23,25,26}, 358 359 suggesting that reintroductions and/or patient transfers could have also contributed to the prolonged nature of these outbreaks. Though our study period concluded in 2022, given the prolonged and 360 361 sporadic nature, we believe it is unlikely that the outbreak has stopped for good.

362

One limitation to our study is that while patients without infection were screened for colonization during the first wave of cases at Hospital #1, comprehensive screening of all the involved hospitals and throughout the entire study period was not performed. This obscures an understanding of the relationship between colonization and subsequent infection during the outbreak and a mechanistic understanding of how *C. parapsilosis* is transmitted within healthcare facilities.

368

The finding of azole-resistant strains from different continents that were very closely related to the 369 strains spreading within healthcare facilities in Berlin highlights the global challenge of antifungal 370 371 resistant pathogens and the emergence of Candida spp that are easily transmitted patient-to-372 patient. It is likely that drug resistance was acquired independently and recently in this lineage. 373 given the close genomic relationship but different resistance mechanisms in strains from Germany, 374 Canada, and South Korea. How this lineage acquired drug resistance and how it has spread across continents are open questions, but we hypothesize that it may have enhanced properties that 375 376 facilitate its transmission and persistence. The observation of highly related clones observed on 377 multiple continents mirrors the behavior of Candida auris. Nearly identical clades of this pathogen have been reported on multiple continents and continue to spread globally ^{27,28}, underscoring the 378 379 fact that C. parapsilosis has the potential to become a problem of similar scale. Additionally, three phylogenetically distinct Y132F lineages of fluconazole-resistant C. parapsilosis were discovered in 380 381 Germany during the study period, each with multiple isolates reported from distinct geographic areas. We also identified six isolates that are resistant by an unknown mechanism, which will be an 382

interesting area to follow up on using genome-wide association approaches. Taken together these
 observations demonstrates that fluconazole-resistant *C. parapsilosis* is endemic in Germany,
 mirroring what has been recently been reported in other countries ³, and highlighting the changing
 epidemiology of the pathogen that clinicians should be aware of.

387

Microsatellite typing in C. parapsilosis is typically performed using four loci and provides a 388 discriminatory power between 0.63²⁹ and 0.99¹⁵. The four loci MLST established in this study 389 achieved a discriminatory power of 0.93, within the range of what is achieved using microsatellites. 390 Importantly, MLST methodology could unambiguously compare samples from >9 years and around 391 392 the world, a task not possible using existing microsatellite strategies based on gel electrophoresis profiles. Taken together, our study provides a high-resolution description of an azole-resistant 393 C. parapsilosis outbreak, identifies hospital transfers as recurring source of pathogen introductions. 394 395 and defines a sequence-based typing scheme for epidemiology and rapid identification of potential 396 outbreaks.

397

398 Data sharing

Raw FASTQ files for novel isolates sequenced in this study were uploaded to the NCBI Sequence 399 400 Read Archive and are publicly available under BioProject PRJNA996760. Accession numbers for the publicly available sequence data used in this study are listed in appendix 2. Genbank records 401 for the Sanger sequencing of the MLST loci performed in this study are listed in appendix 1 p 14. 402 FASTAs containing representative allele sequences for each of the four typing loci are available as 403 404 appendices 4-7. Most data analysed in this study are included within the study or in the appendices. However, remaining datasets can be made available from the corresponding author on reasonable 405 406 request.

407

408 Acknowledgements

We are grateful to Peggy Karanatsiou of the Friedrich Schiller University and Philipp Hupel, Carmen Karkowski, and Christiane Weigel of the NRZMyk for technical assistance. We thank Britta Schweickert of the Robert-Koch-Institute for contributing regional hospital data from the antibiotic consumption surveillance system. We also acknowledge MSD and Pfizer for providing the drugs for antifungal susceptibility testing to the NRZMyk free of charge.

414

415 Funding

This project was supported by The Federal Ministry for Education and Science (Bundesministerium für Bildung und Forschung) within the framework of InfectControl 2020 (Projects FINAR 2.0, grant 03ZZ0834). The work of the German National Reference Center for Invasive Fungal Infections is supported by the Robert Koch Institute from funds provided by the German Ministry of Health (grant 1369-240). AEB is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research

421 358 Foundation) under Germany's Excellence Strategy – EXC 20151 – Project-ID 390813860.

422

423 <u>Contributors</u>

AEB and GW conceptualized the study. PB, FRK, BG, RP, OK, GW and AEB contributed to

investigation, methodology, and formal analysis. PB, GW, and AEB were responsible for visualization.

426 AEB did the statistical analysis. AEB, PB, and GW wrote the original draft. All authors participated in

427 reviewing and editing the manuscript. All authors had full access to all the data in the study and accept

- responsibility for the decision to submit for publication. AEB and GW verified the underlying data of the study.
- 430
- 431 <u>Declaration of Interests</u>
- 432 We declare no competing interests.
- 433

434 **References**

- Tóth, R. *et al.* Candida parapsilosis: From genes to the bedside. *Clin. Microbiol. Rev.* **32**, 1–38 (2019).
- 437 2. Rhodes, J. & Fisher, M. C. Global epidemiology of emerging Candida auris. *Curr. Opin.*438 *Microbiol.* 52, 84–89 (2019).
- 439 3. Daneshnia, F. *et al.* Worldwide emergence of fluconazole-resistant Candida parapsilosis:
 440 current framework and future research roadmap. *Lancet Microbe* 4, e470–e480 (2023).
- 4. Arastehfar, A. *et al.* Clonal Candidemia Outbreak by Candida parapsilosis Carrying Y132F in
 Turkey: Evolution of a Persisting Challenge. *Front. Cell. Infect. Microbiol.* **11**, (2021).
- 443 5. Qi, L. *et al.* Nosocomial outbreak of Candida parapsilosis sensu stricto fungaemia in a neonatal
 444 intensive care unit in China. *J. Hosp. Infect.* **100**, e246–e252 (2018).
- 6. Thomaz, D. Y. *et al.* An Azole-Resistant Candida parapsilosis Outbreak: Clonal Persistence in the Intensive Care Unit of a Brazilian Teaching Hospital. *Front. Microbiol.* **9**, (2018).
- Arastehfar, A. *et al.* First report of candidemia clonal outbreak caused by emerging fluconazoleresistant Candida parapsilosis isolates harboring Y132F and/or Y132F+K143R in Turkey. *Antimicrob. Agents Chemother.* (2020) doi:10.1128/AAC.01001-20.
- Corzo-Leon, D. E., Peacock, M., Rodriguez-Zulueta, P., Salazar-Tamayo, G. J. & MacCallum,
 D. M. General hospital outbreak of invasive candidiasis due to azole-resistant Candida
 parapsilosis associated with an Erg11 Y132F mutation. *Med. Mycol.* 1–8 (2020)
 doi:10.1093/mmy/myaa098.
- Danilo Y. Thomaz, João N. de Almeida Jr. *, O. N. E. S., Gilda M.B. Del Negro, Gabrielle O. M.
 H. Carvalho, V. M. F. G., Maria Emilia B. de Souza, Amir Arastehfar, Carlos H. Camargo, A. L.,
 Motta, Flávia Rossi, David S. Perlin, Maristela P. Freire, Edson Abdala, G., & Benard.
 Environmental clonal spread of azole-resistant Candida parapsilosis with Erg11-Y132F mutation
 causing a large candidemia outbreak in a Brazilian Cancer Referral Center. *J. Fungi* (2021).
- 459 10. Fekkar, A. *et al.* Hospital Outbreak of Fluconazole-Resistant Candida parapsilosis: Arguments
 460 for Clonal Transmission and Long-Term Persistence. *Antimicrob. Agents Chemother.* 65,
 461 e02036-20 (2021).
- 462 11. Guinea, J. *et al.* Whole genome sequencing confirms Candida albicans and Candida
 463 parapsilosis microsatellite sporadic and persistent clones causing outbreaks of candidemia in
 464 neonates. *Med. Mycol.* 60, myab068 (2022).
- Trevijano-Contador, N. *et al.* Global emergence of resistance to fluconazole and voriconazole in
 Candida parapsilosis in tertiary hospitals in Spain during the COVID-19 pandemic. *Open Forum Infect. Dis.* ofac605 (2022) doi:10.1093/ofid/ofac605.

- McTaggart, L. R. *et al.* First Canadian report of transmission of fluconazole-resistant Candida
 parapsilosis within two hospital networks confirmed by genomic analysis. *J. Clin. Microbiol.* **0**,
 e01161-23 (2023).
- 471 14. Presente, S. *et al.* Hospital Clonal Outbreak of Fluconazole-Resistant Candida parapsilosis
 472 Harboring the Y132F ERG11p Substitution in a French Intensive Care Unit. *Antimicrob. Agents*473 *Chemother.* 67, e01130-22 (2023).
- 474 15. Sabino, R. *et al.* New polymorphic microsatellite markers able to distinguish among Candida
 475 parapsilosis sensu stricto isolates. *J. Clin. Microbiol.* 48, 1677–1682 (2010).
- 476 16. Garcia-Hermoso, D., Desnos-Ollivier, M. & Bretagne, S. Typing Candida Species Using
 477 Microsatellite Length Polymorphism and Multilocus Sequence Typing. in *Candida Species:*478 *Methods and Protocols* (eds. Calderone, R. & Cihlar, R.) 199–214 (Springer, New York, NY,
 479 2016). doi:10.1007/978-1-4939-3052-4 15.
- 480 17. Hamprecht, A. *et al.* Candida auris in Germany and Previous Exposure to Foreign Healthcare.
 481 *Emerg. Infect. Dis.* 25, 1763–1765 (2019).
- 18. Lockhart, S. R. *et al.* Simultaneous emergence of multidrug-resistant candida auris on 3
 continents confirmed by whole-genome sequencing and epidemiological analyses. *Clin. Infect. Dis.* 64, 134–140 (2017).
- 485 19. Arastehfar, A. *et al.* Candidemia Among Coronavirus Disease 2019 Patients in Turkey Admitted
 486 to Intensive Care Units: A Retrospective Multicenter Study. *Open Forum Infect. Dis.* 9, ofac078
 487 (2022).
- 488 20. Kim, T. Y. *et al.* Evolution of Fluconazole Resistance Mechanisms and Clonal Types of Candida
 489 parapsilosis Isolates from a Tertiary Care Hospital in South Korea. *Antimicrob. Agents*490 *Chemother.* 66, e00889-22 (2022).
- 491 21. Asadzadeh, M., Dashti, M., Ahmad, S., Alfouzan, W. & Alameer, A. Whole-Genome and
 492 Targeted-Amplicon Sequencing of Fluconazole-Susceptible and -Resistant Candida
 493 parapsilosis Isolates from Kuwait Reveals a Previously Undescribed N1132D Polymorphism in
 494 CDR1. Antimicrob. Agents Chemother. 65, 10.1128/aac.01633-20 (2021).
- 495
 495
 496
 496 related molecular mechanisms in invasive Candida parapsilosis complex isolates: Increase in 497 fluconazole resistance in 21 years. *Mycoses* 64, 823–830 (2021).
- 498 23. Díaz-García, J. *et al.* Evidence of Fluconazole-Resistant Candida parapsilosis Genotypes
 499 Spreading across Hospitals Located in Madrid, Spain and Harboring the Y132F ERG11p
 500 Substitution. *Antimicrob. Agents Chemother.* 66, e00710-22 (2022).
- 501 24. Daneshnia, F. *et al.* Determinants of fluconazole resistance and echinocandin tolerance in C.
 502 parapsilosis isolates causing a large clonal candidemia outbreak among COVID-19 patients in a
 503 Brazilian ICU. *Emerg. Microbes Infect.* **11**, 2264–2274 (2022).
- 504 25. Thomaz, D. Y. *et al.* A Brazilian Inter-Hospital Candidemia Outbreak Caused by Fluconazole-505 Resistant Candida parapsilosis in the COVID-19 Era. *J. Fungi* **8**, 100 (2022).
- Wang, H. *et al.* Investigation of an unrecognized large-scale outbreak of Candida parapsilosis
 sensu stricto fungaemia in a tertiary-care hospital in China. *Sci. Rep.* 6, 27099 (2016).
- 508 27. Chow, N. A. *et al.* Multiple introductions and subsequent transmission of multidrug-resistant
 509 Candida auris in the USA: a molecular epidemiological survey. *Lancet Infect. Dis.* **3099**, 1–8
 510 (2018).
- 28. Chow, N. A. *et al.* Tracing the evolutionary history and global expansion of Candida auris using
 population genomic analyses. *mBio* **11**, 2020.01.06.896548 (2020).
- 513 29. Romeo, O. *et al.* Microsatellite-based genotyping of Candida parapsilosis sensu stricto isolates
- 514 reveals dominance and persistence of a particular epidemiological clone among neonatal 515 intensive care unit patients. *Infect. Genet. Evol.* **13**, 105–108 (2013).

516 Figures



517

518 Figure 1. Timeline and hospital network dynamics of a Candida parapsilosis outbreak in Berlin, Germany. (a) Timeline histogram of the 33 outbreak cases. Dates are taken from the date 519 520 of first positive culture. Color indicates the inpatient hospital at the time of isolation. A single case was identified in an ambulatory patient, which is indicated with "NA" for the inpatient hospital. (b) 521 522 Inpatient stays of the outbreak cases represented as a network, where nodes (large circles) represent hospitals in the Berlin area and edges (lines) represent direct or indirect patient transfers 523 between two institutions. Edge thickness depicts the relative number of transfers between two 524 525 nodes. Individual patient case numbers are indicated within the node and along the edge. For the 526 network, admission and discharge data beginning 12 months prior to the first detected outbreak and 527 extending until the end of 2022 was utilized. (c) Timeline of 21 cases with temporal and spatial 528 overlap. Alternating gray and white fills indicate five patient clusters where temporal and spatial 529 (same ward) overlaps with other outbreak cases could be verified from inpatient records.



530

531 Figure 2. Whole genome phylogeny of Candida parapsilosis isolates from a global distribution and their azole susceptibility profiles and ERG11 polymorphisms. Maximum-532 likelihood phylogeny constructed from SNV data from 51,494 variable positions. Tree is shown 533 rooted at the midpoint. To increase tree readability, samples from the same sequencing study that 534 showed little genetic differentiation were randomly downsampled to a maximum of 6 samples per 535 536 sequencing project - with the exception of the samples described for the first time in our study. Branches are supported by ultrafast bootstrap values of >0.95 unless otherwise indicated. Where 537 available, azole susceptibility data relative to EUCAST breakpoints and ERG11 polymorphisms are 538 539 indicated. The gray dashed box at the top of the phylogeny indicates the Berlin outbreak samples (medium blue) and the closely related samples from Turkey (red-orange), Canada (light green), 540 541 South Korea (dark blue), and Kuwait (dark green) found in public data. Samples that were 542 sequenced in our study and were resistant to one or more azole, but where no polymorphisms in ERG11 were detected, are marked with an *. 543



545 Figure 3. SNV matrix of the German isolates sequenced in this study.

544

Heatmap showing the pairwise SNV differences between the novel German isolates described in this study. Metadata bands indicate (from top to bottom): fluconazole susceptibility, year of sample isolation, and whether the sample is from the city of Berlin (including both outbreak and non-

outbreak strains) or another city in Germany. Boxplot shows the number of pairwise SNV
 differences when the 33 outbreak strains are compared against each other compared to their

pairwise differences with the other German isolates sequenced in this study (outgroup). Significance

552 determined by Mann-Whitney U test, **** indicates p < 0.0001.